Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on April 16, 2009

Stroke. 2009
Published online before print April 16, 2009, doi: 10.1161/STROKEAHA.108.542381
A more recent version of this article appeared on June 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
40/6/2236    most recent
STROKEAHA.108.542381v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meloni, B. P.
Right arrow Articles by Knuckey, N. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meloni, B. P.
Right arrow Articles by Knuckey, N. W.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Hazardous Substances DB
*MAGNESIUM COMPOUNDS
Related Collections
Right arrow Emergency treatment of Stroke
Right arrow Neuroprotectors

Submitted on November 10, 2008
Revised on December 3, 2008
Accepted on December 5, 2008

In Search of Clinical Neuroprotection After Brain Ischemia. The Case for Mild Hypothermia (35°C) and Magnesium

Bruno P. Meloni PhD*; Kym Campbell BVMS; Hongdong Zhu PhD; and Neville W. Knuckey MD

From the Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Australian Neuromuscular Research Institute, Department of Neurosurgery, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.

* To whom correspondence should be addressed. E-mail: meloni{at}cyllene.uwa.edu.au.

Background and Purpose—Brain injury after stroke and other cerebral ischemic events is a leading cause of death and disability worldwide. Our purpose here is to argue in favor of combined mild hypothermia (35°C) and magnesium as an acute neuroprotective treatment to minimize ischemic brain injury.

Methods and Results—Drawing on our own experimental findings with mild hypothermia and magnesium, and in light of the moderate hypothermia trials in cardiac arrest/resuscitation and magnesium trials in ischemic stroke (IMAGES, FAST-Mag), we bring attention to the advantages of mild hypothermia compared with deeper levels of hypothermia, and highlight the existing evidence for its combination with magnesium to provide an effective, safe, economical, and widely applicable neuroprotective treatment after brain ischemia. With respect to effectiveness, our own laboratory has shown that combined mild hypothermia and magnesium treatment has synergistic neuroprotective effects and reduces brain injury when administered several hours after global and focal cerebral ischemia.

Conclusions—Even when delayed, combined treatment with mild hypothermia and magnesium has broad therapeutic potential as a practical neuroprotective strategy. It warrants further experimental investigation and presents a good case for assessment in clinical trials in treating human patients after brain ischemia.


Key words: stroke • cerebral ischemia • magnesium • hypothermia • combination therapy




This article has been cited by other articles:


Home page
Br J AnaesthHome page
M. F. M. James
Magnesium: an emerging drug in anaesthesia
Br. J. Anaesth., October 1, 2009; 103(4): 465 - 467.
[Full Text] [PDF]